Radeep Services

Radeep Services, established on July 6, 1998, is a Singapore-based sole proprietorship specializing in freight transport arrangements and wholesale trade of a diverse range of goods without a dominant product. (companies.sg) The company is headquartered at 77 High Street, #04-06, High Street Plaza, Singapore 179433. While its primary focus is on logistics and wholesale distribution, Radeep Services has a notable presence in the pharmaceutical import sector, particularly in sourcing finished pharmaceutical formulations from India.

Over the period from 2022 to 2026, Radeep Services imported a total of $40,000 USD worth of pharmaceutical products from India, encompassing 30 shipments. The imported products span two therapeutic categories, with a concentration in Advanced Oncology (66.3%) and Biologics & Immunotherapy (33.7%). The top two products imported were Lenvatinib ($27,000 USD) and Adalimumab ($14,000 USD), accounting for 1.3% and 1.1% of the total import value, respectively. This indicates a strategic focus on high-value oncology and immunotherapy treatments.

Radeep Services operates from its central office located at 77 High Street, #04-06, High Street Plaza, Singapore 179433. While specific details about its warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive import activities suggest a well-established distribution network within Singapore. The focus on importing pharmaceutical products from India indicates a streamlined logistics operation capable of handling international shipments efficiently.

In Singapore's pharmaceutical supply chain, Radeep Services functions primarily as an importer and wholesaler. The company's import activities are centered on sourcing finished pharmaceutical formulations from India, which are then distributed within the Singaporean market. This role positions Radeep Services as a key intermediary between Indian pharmaceutical manufacturers and the local healthcare sector, facilitating the availability of specialized treatments in Singapore.

Radeep Services demonstrates a high degree of supplier concentration, with its top five Indian suppliers accounting for 100% of its pharmaceutical imports. The leading suppliers include PHARMA CHOICE LLP and UNIVAAX, each contributing approximately $1.6 million USD in import value. This concentrated sourcing strategy may offer benefits such as volume discounts and streamlined logistics. However, it also introduces risks related to supply chain disruptions, as dependency on a limited number of suppliers can lead to vulnerabilities if any of these suppliers face operational challenges. The stability of these relationships is crucial for maintaining a consistent supply of pharmaceutical products.

The resilience of Radeep Services's supply chain is closely tied to the stability and reliability of its primary Indian suppliers. The company's reliance on a concentrated supplier base means that any disruptions—such as production delays, regulatory issues, or logistical challenges—could significantly impact its ability to meet market demand in Singapore. To mitigate these risks, it would be prudent for Radeep Services to diversify its supplier base and establish contingency plans, including identifying backup suppliers and ensuring compliance with international Good Manufacturing Practice (GMP) standards. Additionally, maintaining a diverse portfolio of pharmaceutical formulations can help buffer against supply chain disruptions.

Radeep Services's concentrated sourcing pattern positions it to leverage strong relationships with its primary suppliers, potentially securing favorable terms and ensuring a steady supply of high-demand pharmaceutical products. For Indian exporters, this presents an opportunity to establish or strengthen partnerships with Radeep Services, particularly in the oncology and immunotherapy segments. However, Indian exporters should be prepared to meet stringent quality standards and regulatory requirements to align with Radeep Services's sourcing criteria.

In Singapore, the Health Sciences Authority (HSA) is the primary regulatory body overseeing the importation and supply of pharmaceutical products. The HSA operates under the Health Products Act and the Medicines Act, ensuring that all health products, including medicines, meet standards of safety, quality, and efficacy. (moh.gov.sg) The regulatory framework requires that all medicinal products imported into Singapore be evaluated and approved by the HSA before they can be supplied in the market. (moh.gov.sg)

Importers of pharmaceutical products into Singapore must obtain the necessary licenses from the HSA. For instance, an 'Import License on Consignment Basis' is required for importers who are neither the registrants nor authorized by the registrant to import a registered therapeutic product. (hsa.gov.sg) Additionally, the HSA mandates that manufacturers provide evidence of compliance with Good Manufacturing Practice (GMP) standards. As of October 1, 2024, all new or generic drug applications must be supported by GMP compliance evidence for drug substance manufacturers.

Pharmaceutical products imported into Singapore must adhere to stringent quality and labeling requirements set by the HSA. This includes batch testing to ensure product safety and efficacy, stability requirements to confirm product shelf-life, and labeling mandates that specify information such as dosage, administration instructions, and storage conditions. Labeling must be in English, and products must comply with serialization mandates to facilitate traceability and prevent counterfeit products.

Between 2024 and 2026, the HSA has implemented several regulatory updates affecting pharmaceutical imports into Singapore. Notably, the requirement for chemical drug substance manufacturers to provide evidence of GMP compliance became mandatory on October 1, 2024, after a one-year grace period. Additionally, the HSA has been actively updating its guidance on the implementation of GMP evidence for drug substance manufacturers, reflecting a commitment to maintaining high standards in pharmaceutical imports.

Radeep Services's focus on importing pharmaceutical products in the Advanced Oncology and Biologics & Immunotherapy categories aligns with global healthcare trends emphasizing specialized and high-demand treatments. The market demand for these products in Singapore is driven by an aging population and an increasing prevalence of chronic diseases, necessitating advanced therapeutic options. By concentrating on these therapeutic areas, Radeep Services positions itself to meet critical healthcare needs and capitalize on a growing market segment.

Radeep Services's sourcing strategy is centered on importing finished pharmaceutical formulations from India, focusing on generic drugs in the oncology and immunotherapy sectors. This approach allows the company to offer cost-effective treatment options while maintaining a high standard of quality. India's robust pharmaceutical manufacturing sector, known for its adherence to international GMP standards, complements Radeep Services's procurement objectives.

With its specialized product mix, Radeep Services primarily serves the hospital and healthcare sectors in Singapore, supplying advanced oncology and immunotherapy treatments. The company's role as a wholesaler enables it to distribute these specialized products to hospitals, clinics, and other healthcare providers, ensuring that patients have access to essential therapies.

There is a realistic opportunity for new Indian suppliers to collaborate with Radeep Services, particularly in the oncology and immunotherapy segments. To capitalize on this opportunity, Indian exporters should focus on meeting the stringent quality standards and regulatory requirements set by the HSA. Additionally, offering competitive pricing and ensuring a reliable supply chain will be crucial in establishing a successful partnership with Radeep Services.

Indian exporters aiming to supply Radeep Services and the Singapore market must ensure that their products are registered with the HSA and comply with GMP standards. Manufacturers must provide evidence of GMP compliance, and products must meet the HSA's quality and labeling requirements. Additionally, importers must obtain the necessary licenses from the HSA, such as the 'Import License on Consignment Basis,' to legally import pharmaceutical products into Singapore.

Indian exporters should initiate contact with Radeep Services by presenting their product portfolios, emphasizing compliance with HSA regulations and GMP standards. Participating in relevant tenders and industry events can also facilitate relationship-building. Understanding the regulatory filing process with the HSA and preparing the necessary documentation will be essential. Given the regulatory complexities, a timeline of several months may be required to establish a partnership and achieve product registration in Singapore.